Program Offering and Eligibility
With the Evrysdi Co-pay Program:
- You pay as little as $5 per 30-day supply of Evrysdi
- The rest of your co-pay or co-insurance is covered, up to $25,000 in assistance per calendar year for drug costs
- There are no income requirements for this program
YOU ARE ELIGIBLE IF YOU:
- Have been prescribed Evrysdi for an FDA-approved indication
- Are 18 years of age or older, or have a caregiver or have a legally authorized person to manage the patient's co-pay assistance
- Have commercial (private or non-governmental) insurance.* This includes plans available through state and federal health insurance exchanges
- Reside and receive treatment in the United States or U.S. Territories
- Are not receiving assistance through the Genentech Patient Foundation or any other charitable organization for the same expenses covered by the program
- Are not a government beneficiary and/or participant in a federal or state-funded health insurance program (e.g., Medicare, Medicare Advantage, Medigap, Medicaid, VA, DoD, TRICARE)
*Commercial insurance includes plans you receive from your job or plans from the Health Insurance Marketplace. Government programs like Medicare and Medicaid are not commercial insurance.
If you are not eligible for the Evrysdi Co-pay Program, there may be other options for co-pay assistance. Call (833) 387-9734 or visit Genentech-Access.com/Evrysdi/patients to learn more.
What is Evrysdi?
Evrysdi is a prescription medicine used to treat spinal muscular atrophy (SMA) in children and adults.
Important Safety Information
- Before taking Evrysdi, tell your healthcare provider about all of your medical conditions, including if you:
- are pregnant or plan to become pregnant, as Evrysdi may harm your unborn baby. Ask your healthcare provider for advice before taking this medicine
- are a woman who can become pregnant:
- Before you start your treatment with Evrysdi, your healthcare provider may test you for pregnancy
- Talk to your healthcare provider about birth control methods that may be right for you. Use birth control while on treatment and for at least 1 month after stopping Evrysdi
- are an adult male. Evrysdi may affect a man's ability to have children (fertility). Ask a healthcare provider for advice before taking this medicine
- are breastfeeding or plan to breastfeed. It is not known if Evrysdi passes into breast milk and may harm your baby
- Tell your healthcare provider about all the medicines you take
- You should receive Evrysdi from the pharmacy as a liquid. If the medicine in the bottle is a powder, do not use it. Contact your pharmacist for a replacement
- Avoid getting Evrysdi on your skin or in your eyes. If Evrysdi gets on your skin, wash the area with soap and water. If Evrysdi gets in your eyes, rinse your eyes with water
- The most common side effects of Evrysdi include:
- For later-onset SMA:
- For infantile-onset SMA:
- runny nose, sneezing and sore throat (upper respiratory infection)
- lung infection (lower respiratory infection)
These are not all of the possible side effects of Evrysdi. For more information on the risk and benefits profile of Evrysdi, ask your healthcare provider or pharmacist.
You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.
Please see accompanying full Prescribing Information for additional Important Safety Information.